Product
Tetanus, diphtheria, and acellular pertussis vaccine
Aliases
Tdap
1 clinical trial
2 indications
Indication
Multiple SclerosisIndication
Relapsing-RemittingClinical trial
A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying TherapyStatus: Completed, Estimated PCD: 2023-11-15